



# An Auto-luminescent Fluorescent BCG Whole Blood Assay to Enable Evaluation of Paediatric Mycobacterial Responses Using Minimal Blood Volumes

Robindra Basu Roy<sup>1,2\*†</sup>, Basil Sambou<sup>2</sup>, Iria Uhia<sup>3</sup>, Sophie Roetync<sup>2</sup>, Brian D. Robertson<sup>3</sup> and Beate Kampmann<sup>1,2,4</sup>

## OPEN ACCESS

### Edited by:

Emmanuel André,  
KU Leuven, Belgium

### Reviewed by:

Rinawati Rohsiswatmo,  
RSUPN Dr. Cipto Mangunkusumo,  
Indonesia  
Danilo Buonsenso,  
University Cattolica del Sacro Cuore,  
Italy

### \*Correspondence:

Robindra Basu Roy  
robin.basu-roy@lshtm.ac.uk

### †Present Address:

Robindra Basu Roy,  
Department of Clinical Research,  
London School of Hygiene & Tropical  
Medicine, London, United Kingdom

### Specialty section:

This article was submitted to  
Pediatric Infectious Diseases,  
a section of the journal  
Frontiers in Pediatrics

Received: 20 October 2018

Accepted: 01 April 2019

Published: 30 April 2019

### Citation:

Basu Roy R, Sambou B, Uhia I,  
Roetync S, Robertson BD and  
Kampmann B (2019) An  
Auto-luminescent Fluorescent BCG  
Whole Blood Assay to Enable  
Evaluation of Paediatric Mycobacterial  
Responses Using Minimal Blood  
Volumes. *Front. Pediatr.* 7:151.  
doi: 10.3389/fped.2019.00151

<sup>1</sup> Department of Paediatrics, Centre for International Child Health, Imperial College London, London, United Kingdom,

<sup>2</sup> Vaccines & Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine (LSHTM),

Banjul, The Gambia, <sup>3</sup> MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London,

United Kingdom, <sup>4</sup> Faculty of Infectious and Tropical Diseases, The Vaccine Centre, London School of Hygiene and Tropical  
Medicine, London, United Kingdom

**Introduction:** Understanding protective human immunity against mycobacteria is critical to developing and evaluating new vaccines against tuberculosis. Children are the most susceptible population to infection, disease, and death from tuberculosis, but also have the strongest evidence of BCG-inducible protection. Limited amounts of blood can be obtained for research purposes in paediatrics and therefore there is a need for high-yield, low-volume, human immunology assays.

**Methods:** We transformed BCG Danish with plasmids encoding luciferase full operon derived from *Photobacterium luminescens* together with Green Fluorescent Protein and antibiotic selection markers. We characterised the luminescent and fluorescent properties of this recombinant BCG strain (BCG-GFP-LuxFO) using a luminometer and flow cytometry and developed a paediatric whole blood *in vitro* infection model.

**Results:** Luminescence of BCG-GFP-LuxFO correlated with optical density (Spearman Rank Correlation coefficient  $r = 0.985$ ,  $p < 0.0001$ ) and colony forming units (CFUs) in liquid culture medium ( $r = 0.971$ ,  $p < 0.0001$ ). Fluorescence of BCG-GFP-LuxFO in paediatric whole blood was confirmed by flow cytometry in granulocytes and monocytes 1 h following infection. Luminescence of BCG-GFP-LuxFO in whole blood corresponded with CFUs ( $r = 0.7123$ ,  $p < 0.0001$ ).

**Conclusion:** The BCG-GFP-LuxFO assay requires 225  $\mu$ L whole blood per sample, from which serial luminescence measurements can be obtained, together with biochemical analysis of supernatants and cellular assay applications using its fluorescent properties. This offers the opportunity to study human-mycobacterial interactions using multiple experimental modalities with only minimal blood volumes. It is therefore a valuable method for investigating paediatric immunity to tuberculosis.

**Keywords:** tuberculosis, paediatric, BCG, immunology, mycobacterial growth inhibition assay

## INTRODUCTION

An understanding of protective immunity to tuberculosis is required to inform vaccine design, contribute to the World Health Organization's Roadmap to end TB in children and adolescents, and achieve the goal of zero childhood tuberculosis deaths (1–6). The study of human immunity to mycobacteria is key to a better understanding of the disease, given the inherent constraints on how much can be extrapolated from animal models (7–10). Understanding paediatric immune responses is of particular importance as young children are the most susceptible to developing infection, disease, or dying following exposure, but also the group for whom there is the strongest evidence of BCG-inducible protection against tuberculosis (11–15). However, phlebotomy is technically challenging in children, can be distressing for the child and family, and research blood sample volumes are small (16). As a consequence, the number of studies conducted in children remains very limited, and a critical need to refine laboratory methodology remains. New methods need to maximise the scientific yield from small volumes of blood from children affected by *M. tuberculosis* who participate in research studies.

One widely published method to measure human mycobacterial immunity is the *lux* assay (17–27). The BCG-*lux* assay involves a 96 h incubation of whole blood in culture medium with BCG-*lux*, a strain of BCG constitutively expressing *luxAB* genes, which encode a luciferase enzyme from *Vibrio harveyii* on a plasmid together with a gene encoding hygromycin resistance to enable selection and prevent loss of the plasmid (17–27). Luminescence of samples is measured using a luminometer at baseline and 96 hours following centrifugation and red cell lysis of the pellets, dilution and addition of the luciferase substrate. The assay also provides the opportunity to store supernatants for subsequent analysis. A growth ratio is derived by the luminescence measured at 96 h divided by that measured at baseline. Another mycobacterial growth assay, the Mycobacterial Growth Inhibition Assay, measures the Time to Detection in an automated mycobacterial culture system (MGIT) of a lysed sample of whole blood or peripheral blood mononuclear cells that has been co-cultured with an inoculum of mycobacteria for 96 h (28–34).

We aimed to develop an improved *lux* whole blood assay using an auto-luminescent recombinant BCG strain expressing the luciferase full operon derived from *Photobacterium luminescens*, which includes the genes encoding the bacterial luciferase enzyme and the genes for the synthesis of the substrate for the luminescence reaction (35–37). This would enable quantification of luminescence in a continuous manner from the same sample, and thereby decrease the blood volumes required to evaluate mycobacterial growth. Co-expression of a green fluorescent protein would enable cellular assays on cell pellets in addition to biochemical evaluation of supernatants, further enhancing the scientific yield from a given volume of blood.

## MATERIALS AND METHODS

### Mycobacterial Culture Methods

BCG is a hazard group 2 organism and therefore all experimental work was conducted in category Level 2 laboratories. Liquid medium was prepared with 4.7 g of 7H9 Middlebrook dried broth (Fluka/Sigma-Aldrich, Gillingham, UK), 2.5 ml of 20% Tween 80 (Acros Organics/Thermo Fisher Scientific, Waltham, MA, USA), 4 ml of 50% glycerol (VWR, Radnor, PA, USA), and dissolved in 893.5 ml of dH<sub>2</sub>O. This was then autoclaved for 15 min at 100 kPa at 121°C. Once cooled 100 ml of Albumin Dextrose Catalase (ADC) supplement (BD, Franklin Lakes, NJ, USA) was added and selection antibiotics at the specified concentrations (Hygromycin, Sigma-Aldrich, Gillingham, UK; Kanamycin, Glyco/Life Technologies, Carlsbad, CA, USA). Forty microlitre of 20% Tween 80 was added for each 15 ml of medium. Solid medium was prepared with 21 g of 7H11 agar (Fluka/Sigma-Aldrich, Gillingham, UK) and 10 ml 50% glycerol made up to a final volume of 900 ml with dH<sub>2</sub>O in a 1 L bottle and autoclaved for 15 min at 100 kPa at 121°C. Once cooled, 100 ml of Oleic acid Albumin Dextrose Catalase (OADC) supplement (BD, Franklin Lakes, NJ, USA) was added and selection antibiotics at the specified concentrations. Colony Forming Units (CFU) were counted using serial dilutions in sterile Phosphate Buffered Saline of 10 μL of the experimental sample plated onto solid culture medium after 21 days. Liquid and solid cultures were incubated at 37°C. Optical density (OD<sub>600</sub>) of 0.5 ml volumes of bacteria in liquid culture was measured using a Biophotometer Plus spectrophotometer (Eppendorf, Hamburg, Germany).

### Transformation of BCG

The parent strain was BCG Danish (Staten Serum Institute, Copenhagen, Denmark). The following plasmids were used: pMV306DIhsp+LuxG13: Kanamycin resistance integrase-free integrative reporter plasmid harbouring the Luciferase Full Operon (*Photobacterium luminescens*) (35, 37, 38). (pMV306DIhsp+LuxG13, Addgene plasmid # 49999) (37); pBS-Int: a suicide plasmid that expresses the integrase gene necessary for the integration of pMV306DIhsp+LuxG13 into the chromosome after electroporation. (Addgene plasmid # 50000); pGFPHYG2: A hygromycin resistance replicative plasmid that expresses *gfpmut3*, encoding Green Fluorescent Protein, and (39) (pGFPHYG2, Addgene plasmid # 30173).

Transformations were carried out as per the protocol of Goude and Parish (40) Briefly, 50 mL of culture in logarithmic growth phase were centrifuged at 3000 × g for 10 min at room temperature. The cells were washed twice with 50 ml and then 20 ml pre-warmed 10% glycerol plus 0.05% Tween 80. The cells were resuspended in 500 μL of 10% glycerol and 200 μL was transferred into electroporation cuvettes. One hundred nanograms DNA of each plasmid was used. Electroporation was carried out with a single pulse of 2.5 kV, 25 μF with the pulse-controller resistance set at 1,000 Ω resistance. The suspension was then immediately transferred into 10 mL 7H9 media and incubated without antibiotics for 16 h. Bacteria were harvested by centrifugation at 3000 × g for 10 min and dilutions were plated

**TABLE 1** | Demographic characteristics of 9 participants.

|                                           |               |
|-------------------------------------------|---------------|
| Median age in years (interquartile range) | 7.3 (6.5–8.5) |
| Male:Female ratio                         | 1:2           |
| TST result > 10 mm                        | 3             |

out on 7H11 plates with kanamycin at 20 µg/mL and hygromycin at 50 µg/mL. Plates were incubated at 37°C until discrete colonies appeared. Colonies were picked and incubated in 7H9 liquid media at 37°C. Stocks were frozen down in 15% glycerol. The resultant strain is named BCG-GFP-LuxFO.

## Quantification of Luminescence and Detection of Fluorescence of Bacteria

Luminescence of BCG-GFP-LuxFO was quantified in Relative Light Units/second (RLU/s) using the Sirius Tube Luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany) immediately following removal from the incubator.

Direct fluorescence of bacteria was measured in a 1:1 mixture of non-fluorescent BCG and BCG-GFP-LuxFO fixed in 2% paraformaldehyde using a LSRII Fortessa flow cytometer (BD, San Jose, CA, USA).

## Paediatric Whole Blood BCG-GFP-LuxFO Assays

Whole blood was collected in lithium-heparin vacutainer tubes (BD, Wokingham, UK) from children aged 5–15 years old participating in a household contact tuberculosis study in The Gambia (41–44). Each independent experiment consisted of participants who were selected based upon having had household exposure to the same adult with smear-positive pulmonary tuberculosis, no symptoms of tuberculosis, and included children with positive and negative tuberculin skin test responses as part of a larger study exploring factors influencing latent tuberculosis infection in children. Approvals were obtained from The MRC Unit The Gambia Scientific Coordinating Committee and The Gambia Government/MRC Joint Ethics Committee (SCC1405). Experiments were carried out in 2015 at MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine. Participant characteristics are shown in **Table 1**.

A vial of BCG-GFP-LuxFO stored in 15% glycerol at –70°C was thawed and added to 15 ml 7H9 Middlebrook broth supplemented with ADC and kanamycin (final concentration 20 µg/ml) and hygromycin (final concentration 50 µg/ml) +40 µl 20% Tween 80 in a 250 ml Erlenmeyer flask (Corning B.V Life Sciences, Amsterdam, The Netherlands). This was incubated in an orbital shaking incubator at 37°C with daily measurements of 0.5 ml samples for luminescence and optical density. Further liquid medium was added as required to maintain the bacteria in logarithmic growth phase until the day of the assay. Immediately prior to the blood samples being taken, an aliquot of the stock in logarithmic phase was diluted down to  $3.3 \times 10^5$  RLU/ml/s BCG-GFP-LuxFO. This concentration of BCG-GFP-LuxFO gave baseline luminescence readings of whole blood samples 10-fold higher than the experimentally determined detection threshold of the luminometer used for this assay to enable a dynamic range.

A schematic of the paediatric whole blood assay is shown in **Figure 1**. Whole blood was mixed in a ratio of 1:1 with RPMI 1640 culture medium (Sigma-Aldrich, Gillingham, UK) containing 2.5% 1M HEPES buffer and 1% L-glutamine (both Sigma-Aldrich). The BCG-GFP-LuxFO in 7H9–0.05% Tween 80-ADC with kanamycin at 20 µg/mL and hygromycin at 50 µg/mL was added at a ratio of 1 part BCG-GFP-LuxFO: 9 parts whole blood in culture medium. For the medium only control samples, bacterial medium alone was added in the same ratio of 1:9. Four 0.5 ml aliquots of each experimental condition were placed into sterile lidded 75 × 12 mm standard tubes (Corning B.V Life Sciences, Amsterdam, The Netherlands). This equates to a total volume of 900 µL whole blood for each condition with triplicate tubes for quantifying luminescence and a fourth tube to enable determination of CFU during this method development. Triplicate growth controls of the recently diluted BCG-GFP-LuxFO in 1:9 ratio with further liquid medium were prepared in parallel to confirm that the bacteria remained in logarithmic growth phase at the time of inoculation.

## Detection of Fluorescence in Paediatric Whole Blood

One hour after BCG-GFP-LuxFO or medium alone were added, samples were centrifuged at 2,000 g for 10 min. The cell pellet was resuspended in RPMI with 2 mM EDTA to remove adherent cells, and red cells were then lysed with a 10 min incubation with red cell lysis buffer (eBioscience, Thermo Fisher Scientific, Waltham, MA, USA), washed, a further 10 min incubation with red cell lysis buffer and then washed twice. 0.4 µL Live/Dead Aqua (Thermo Fisher Scientific, Waltham, MA, USA) was added and incubated for 20 min in the dark at room temperature. Cells were then washed and fixed in FACS Lysing solution for 10 min (BD, San Jose, CA, USA), washed twice and resuspended in PBS with 2% Fetal Calf Serum and 0.5 mM EDTA. Data were acquired with a LSRII Flow Cytometer (BD, San Jose, CA, USA). Cells were first gated based on their light scatter properties and cellular debris were excluded. Only singlets and live cells were then included in the analysis. Compensation was calculated for each fluorescence using single colour stained whole blood samples (i.e., medium only control sample stained with Live/Dead dye and unstained BCG-GFP-LuxFO infected sample). Data analysis was performed using FlowJo v10.5.3 for Mac (Treestar Inc., USA).



## Detection of Luminescence in Paediatric Whole Blood



Luminescence of each whole blood aliquot was measured using the Sirius Tube Luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany) immediately following removal of the tubes from the incubator. Luminescence was measured 1 h after the bacteria were added to ensure that the sample had equilibrated to 37°C in the incubator, and at 24, 48, 72, and 96 h. Three luminescence measurements at each time point were recorded, and the mean of these three measurements was recorded. At each time point, mean background luminescence from three medium-only control samples was also measured and then subtracted. Ten microlitre aliquots were removed

from a fourth tube every 24h and dilutions were plated for determination of CFUs and correlation to the luminescence measurements in the same tube.

### Statistical Methods

Spearman's Rank Correlation coefficients and coefficients of variation were calculated using Prism 7 for MacOS





X (Graphpad Software, La Jolla, CA, USA). Two-tailed significance testing was applied with  $p < 0.05$  considered to be statistically significant.

## RESULTS

### Characteristics of BCG-GFP-LuxFO in Liquid Culture

BCG-GFP-LuxFO demonstrated logarithmic growth in liquid culture medium (Figure 2A) with luminescence and optical density correlating with Spearman Rank Correlation coefficient of 0.985 (95% confidence interval 0.956–0.995,  $p < 0.0001$ ) (Figure 2B). Colony forming units and luminescence of BCG-GFP-LuxFO in liquid culture medium correlated with Spearman rank correlation coefficient  $r = 0.9714$  (95% CI: 0.9112–0.9910;  $p < 0.0001$ ) (Figure 3). The RLU:CFU ratio for BCG-GFP-LuxFO was 0.05 RLU: 1 CFU. Fluorescence of BCG-GFP-LuxFO was confirmed by flow cytometry (Figure 4).

### Fluorescence in Paediatric Whole Blood Assay

Following centrifugation to obtain the cell pellet, 350–400  $\mu\text{L}$  of supernatant could be stored from each 0.5 ml aliquot. One hour after infection with BCG-GFP-LuxFO, 15% of all cells were GFP positive, with 26% of granulocytes, 21% of monocytes, and 0.1% of lymphocytes demonstrating fluorescence based on cell size and granularity (Figure 5).

### Luminescence in Paediatric Whole Blood Assay


Data were analysed from nine children in three independent experiments and five timepoints. Luminescence and CFUs correlated with Spearman rank correlation coefficient  $r = 0.7123$  (95%CI: 0.5230–0.8346;  $p < 0.0001$ ) (Figure 6). Mean coefficients of variation in luminescence data across these experiments were 7.65% for (a) the three measurements of each tube and 11.5% for (b) the three replicates for each child.

## DISCUSSION


We have developed and evaluated an auto-luminescent fluorescent BCG reporter strain that demonstrates robust correlations between luminescence, optical density, and CFUs in liquid culture. In a high TB-endemicity setting with paediatric whole blood samples, we were able to demonstrate across three independent experiments, nine paediatric subjects, and five timepoints that luminescence and CFU correlated significantly. The BCG-GFP-LuxFO assay enables serial non-destructive luminescence measurements over 96 h where each tube contains 225  $\mu\text{L}$  whole blood. Existing assays require 450  $\mu\text{L}$  to generate a single 96 h growth ratio value in the *lux* assay or 300  $\mu\text{L}$  of whole blood to generate the Time to Detection in the Mycobacterial Growth Inhibition Assay (23, 32, 34). The ability to quantify luminescence in a non-destructive manner combined with the fluorescent nature of BCG-GFP-LuxFO means that following measurement, samples can be centrifuged to carry out biochemical analyses on the supernatants and cellular analyses on the cell pellet as required.

BCG-GFP-LuxFO has a relatively low RLU:CFU of 0.05 RLU: 1 CFU, which likely reflects the associated metabolic costs of constitutive expression of the whole luciferase operon (35–37). This low RLU:CFU ratio means that the multiplicity of infection is higher than with the *lux* assay. However, as measuring luminescence in the original *lux* assay involves lysis of red blood cells, vortexing with glass beads, and dilution steps, there is considerable decrease in experimental time with the BCG-GFP-LuxFO assay compared to the *lux* assay, and the potential for automated luminescence measurement (20).

The BCG-GFP-LuxFO assay contributes to the range of immunological methods available to study human whole blood responses to mycobacteria. Studies of human whole blood have made many important contributions to understanding human mycobacterial immunity and originally led to the identification of mendelian susceptibility genes and pathways (17, 18, 27,



**FIGURE 5 |** Flow cytometric detection of fluorescence of BCG-GFP-LuxFO in whole blood assay. **(A)** Within the live cell population, GFP- and GFP+ cells were determined, respectively. **(B)** Within the live cell population, cells were then gated on either granulocytes (in red), monocytes (in green), or lymphocytes (in blue), distinguishable by their size and granularity using forward scatter (FSC)/side scatter (SSC) gate. The gate GFP-/GFP+ populations were set based on the medium only negative control so that the frequency of GFP+ cells = 0% for each cell population. For each plot, the GFP- population is reported in the top left, and the GFP+ population in the top right. Representative data shown from samples from two children one hour after BCG-GFP-LuxFO was added.



**FIGURE 6 |** Correlation between luminescence and colony forming units in BCG-GFP-LuxFO paediatric whole blood assay. *n* = 45 pairs of observations (samples from three experiments, from 9 children at 5 time points). Spearman rank correlation coefficient *r* = 0.7123 (95%CI: 0.5230–0.8346; *p* < 0.0001).

45, 46). Studying whole blood in paediatric populations with tuberculosis has highlighted distinct gene expression signatures with diagnostic potential (47). In light of recent advances in the immunological definition of the TB spectrum, the BCG-GFP-LuxFO assay has potential to compliment other research methods in characterising the human host response (8, 46, 48–50).

Whole blood is critical to study the role of neutrophils in tuberculosis: they are known to be the most common cell type infected in whole blood samples taken from adult donors

(51); enhance macrophage responses (52); and drive a type I interferon-inducible transcript signature in adults (45). The small volume requirements for the BCG-GFP-LuxFO assay combined with the high data yield means that it is well-suited to research in paediatric populations affected by tuberculosis.

### ETHICS STATEMENT

This study was carried out in accordance with the recommendations of The MRC Unit The Gambia Scientific Coordinating Committee and The Gambia Government/MRC Joint Ethics Committee (Reference number: SCC1405), with written informed consent from all families. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

### AUTHOR CONTRIBUTIONS

RB, IU, BK, and BR conceived and designed the work. IU and RB carried out the transformations of BCG. RB and BS developed and carried out the whole blood assays. SR and RB carried out the flow cytometry experiments and analysis. RB drafted the work and all authors revised it critically for important intellectual content and are accountable for all aspects of the work.

### FUNDING

RB’s Clinical Research Training Fellowship was jointly funded by the UK Medical Research Council (MRC) and the UK

Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union (MR/K023446/1). BK is supported by MRC Program Grant MR/K011944/1, MRC-GCRF Foundation award MR/P024270/1, and NIHR Senior Fellowship SRF-2009-02-07. IU was funded by a postdoctoral fellowship from the Fundación Alfonso Martín Escudero (2012 call) and a grant from the Imperial College Trust (P08829) to BR.

## REFERENCES

1. The World Health Organization Stop TB Partnership. *No More Crying, No More Dying. Towards Zero TB Deaths in Children*. Geneva (2012).
2. Stop TB Partnership. *The Global Plan to End TB 2016 - 2020: The Paradigm Shift*. Geneva (2015).
3. World Health Organization. *Roadmap Towards Ending TB in Children and Adolescents*. Geneva (2018).
4. Treatment Action Group, Child & Adolescent TB Working Group. *Research Priorities for Paediatric Tuberculosis*. (2018). Available online at: <http://www.treatmentactiongroup.org/content/research-priorities-pediatric-tuberculosis> (accessed October 6, 2018).
5. Gardiner JL, Karp CL. Transformative tools for tackling tuberculosis. *J Exp Med*. (2015) 212:1759–69. doi: 10.1084/jem.20151468
6. Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. *Immunol Rev*. (2015) 264:363–81. doi: 10.1111/imr.12270
7. Williams A, Orme IM. Animal models of tuberculosis: an overview. *Microbiol Spectr*. (2016) 4: TBTB2-0004-2015. doi: 10.1128/microbiolspec
8. Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis. *Microbiol Spectr*. (2017) 5:TBTB2-0016-2016. doi: 10.1128/microbiolspec.TBTB2-0016-2016
9. Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AKK, et al. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. *Tuberculosis*. (2013) 93:143–9. doi: 10.1016/j.tube.2013.01.003
10. Kashangura R, Sena ES, Young T, Garner P. Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. *Int J Epidemiol*. (2015) 44:1970–81. doi: 10.1093/ije/dyv142
11. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis. *BMJ*. (2014) 349:g4643. doi: 10.1136/bmj.g4643
12. Basu Roy R, Whittaker E, Seddon JA, Kampmann B. Tuberculosis susceptibility and protection in children. *Lancet Infect Dis*. (2019) 19:e96–108. doi: 10.1016/S1473-3099(18)30157-9
13. Higgins JPT, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. *BMJ*. (2016) 355:i5170. doi: 10.1136/bmj.i5170
14. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis*. (2014) 58:470–80. doi: 10.1093/cid/cit790
15. Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, Donald P, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis*. (2017) 17:285–95. doi: 10.1016/S1473-3099(16)30474-1
16. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull World Health Organ*. (2011) 89:46–53. doi: 10.2471/BLT.10.080010
17. Kampmann B, Tena-Coki GN, Nicol MP, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. *AIDS*. (2006) 20:1011–8. doi: 10.1097/01.aids.0000222073.45372.ce

## ACKNOWLEDGMENTS

We are grateful to the participants and their families for agreeing to take part in this work, and Muhamed Sissoko for his help in recruitment. The method development described in this article is included in the Doctor of Philosophy thesis “Protection from *Mycobacterium tuberculosis* infection: Learning from exposed but uninfected children” by RB, awarded by Imperial College London on 1st March 2018.

18. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, et al. Neutrophil-mediated innate immune resistance to mycobacteria. *J Clin Invest*. (2007) 117:1988–94. doi: 10.1172/JCI31097
19. Kampmann B, Tena GN, Mzazi S, Eley B, Young DB, Levin M. Novel human *in vitro* system for evaluating antimycobacterial vaccines. *Infect Immun*. (2004) 72:6401–7. doi: 10.1128/IAI.72.11.6401-6407.2004
20. Kampmann B, Gaora PO, Snewin V, Gares MP, Young DB, Levin M. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. *J Infect Dis*. (2000) 182:895–901. doi: 10.1086/315766
21. Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective *Mycobacterium tuberculosis* immunity. *J Infect Dis*. (2002) 186:1448–57. doi: 10.1086/344359
22. Newton S, Martineau A, Kampmann B. A functional whole blood assay to measure viability of mycobacteria, using reporter-gene tagged BCG or M.Tb (BCG lux/M.Tb lux). *J Vis Exp*. (2011) e3332. doi: 10.3791/3332
23. Burl S, Holder BS, Lo BKM, Kampmann B. Optimisation of a functional mycobacterial growth-inhibition assay to improve its suitability for infant TB vaccine studies. *J Immunol Methods*. (2013) 394:121–4. doi: 10.1016/j.jim.2013.05.006
24. Tena GN, Young DB, Eley B, Henderson H, Nicol MP, Levin M, et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. *J Infect Dis*. (2003) 187:1544–51. doi: 10.1086/374799
25. Cheon S-H, Kampmann B, Hise AG, Phillips M, Song H-Y, Landen K, et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. *Clin Diagn Lab Immunol*. (2002) 9:901–7. doi: 10.1128/CDLI.9.4.901-907.2002
26. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. *J Clin Invest*. (2011) 121:3554–63. doi: 10.1172/JCI46095
27. Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. *Science*. (2006) 314:454–8. doi: 10.1126/science.1133515
28. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*. (2016) 7:11290. doi: 10.1038/ncomms11290
29. Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al. Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-naïve Adults: a randomized, active-controlled, first-in-human Phase 1 Trial. *EBioMedicine*. (2016) 7:278–86. doi: 10.1016/j.ebiom.2016.04.010
30. Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, et al. The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project 2010–2014. *Clin Vaccine Immunol*. (2017) 24:e00142-17. doi: 10.1128/CI.00142-17
31. Tanner R, O’Shea MK, Fletcher HA, McShane H. *In vitro* mycobacterial growth inhibition assays: a tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. *Vaccine*. (2016) 34:4656–65. doi: 10.1016/j.vaccine.2016.07.058
32. Wallis RS, Palaci M, Vinhas S, Hise AG, Ribeiro FC, Landen K, et al. A whole blood bactericidal assay for tuberculosis. *J Infect Dis*. (2001) 183:1300–3. doi: 10.1086/319679

33. Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, Peres RL, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. *J Infect Dis.* (2003) 187:270–8. doi: 10.1086/346053
34. Baguma R, Penn-Nicholson A, Smit E, Erasmus M, Day J, Makhethe L, et al. Application of a whole blood mycobacterial growth inhibition assay to study immunity against *Mycobacterium tuberculosis* in a high tuberculosis burden population. *PLoS ONE.* (2017) 12:e0184563. doi: 10.1371/journal.pone.0184563
35. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, et al. Optimisation of bioluminescent reporters for use with mycobacteria. *PLoS ONE.* (2010) 5:e10777. doi: 10.1371/journal.pone.0010777
36. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. Rapid measurement of antituberculosis drug activity *in vitro* and in macrophages using bioluminescence. *J Antimicrob Chemother.* (2012) 67:404–14. doi: 10.1093/jac/dkr472
37. Andreu N, Zelmer A, Sampson SL, Ikei M, Bancroft GJ, Schaible UE, et al. Rapid *in vivo* assessment of drug efficacy against *Mycobacterium tuberculosis* using an improved firefly luciferase. *J Antimicrob Chemother.* (2013) 68:2118–27. doi: 10.1093/jac/dkt155
38. Qazi SNA, Counil E, Morrissey J, Rees CED, Cockayne A, Winzer K, et al. *agr* expression precedes escape of internalized staphylococcus aureus from the host endosome. *Infect Immun.* (2001) 69:7074–82. doi: 10.1128/IAI.69.11.7074-7082.2001
39. Cosma CL, Klein K, Kim R, Beery D, Ramakrishnan L. *Mycobacterium marinum* Erp is a virulence determinant required for cell wall integrity and intracellular survival. *Infect Immun.* (2006) 74:3125–33. doi: 10.1128/IAI.02061-05
40. Goude R, Parish T. Electroporation of *Mycobacteria*. *Methods Mol Biol.* (2009) 465:203–15. doi: 10.1007/978-1-59745-207-6\_13
41. Togun TO, Egere U, Gomez MP, Sillah AK, Daramy M, Tientcheu LD, et al. No added value of interferon- $\gamma$  release to a prediction model for childhood tuberculosis. *Eur Respir J.* (2016) 47:223–32. doi: 10.1183/13993003.00890-2015
42. Egere U, Sillah A, Togun T, Kandeh S, Cole F, Jallow A, et al. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. *Public Heal Action.* (2016) 6:226–31. doi: 10.5588/pha.16.0073
43. Togun TO, Egere U, Sillah AK, Ayorinde A, Mendy F, Tientcheu L, et al. Contribution of Xpert MTB/RIF to the diagnosis of pulmonary tuberculosis among TB-exposed children in The Gambia. *Int J Tuberc Lung Dis.* (2015) 19:1091–7. doi: 10.5588/ijtld.15.0228
44. Egere U, Togun T, Sillah A, Mendy F, Otu J, Hoelscher M, et al. Identifying children with tuberculosis among household contacts in The Gambia. *Int J Tuberc Lung Dis.* (2017) 21:46–52. doi: 10.5588/ijtld.16.0289
45. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch S, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature.* (2010) 466:973–7. doi: 10.1038/nature09247
46. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *Lancet.* (2016) 387:2312–22. doi: 10.1016/S0140-6736(15)01316-1
47. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. *N Engl J Med.* (2014) 370:1712–23. doi: 10.1056/NEJMoa1303657
48. Sali M, Buonsenso D, D'Alfonso P, De Maio F, Ceccarelli M, Battah B, et al. Combined use of quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. *J Infect.* (2018) 77:526–33. doi: 10.1016/j.jinf.2018.09.011
49. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose positron emission and computed tomography. *Nat Med.* (2016) 22:1090–93. doi: 10.1038/nm.4161
50. Weiner J, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, et al. Metabolite changes in blood predict the onset of tuberculosis. *Nat Commun.* (2018) 9:5208. doi: 10.1038/s41467-018-07635-7
51. Eum S-Y, Kong J-H, Hong M-S, Lee Y-J, Kim J-H, Hwang S-H, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. *Chest.* (2010) 137:122–8. doi: 10.1378/chest.09-0903
52. Andersson H, Andersson B, Eklund D, Ngho E, Persson A, Svensson K, et al. Apoptotic neutrophils augment the inflammatory response to mycobacterium tuberculosis infection in human macrophages. *PLoS ONE.* (2014) 9:e101514. doi: 10.1371/journal.pone.0101514

**Conflict of Interest Statement:** BK holds a patent for a paediatric diagnostic biosignature. RB was a consultant for FIND, Geneva, a non-profit organization, from 2014 to 2016.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Basu Roy, Sambou, Uhia, Roetync, Robertson and Kampmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.